{"entity":{"id":"nct06698965","kind":"trial","name":"Efficacy and Safety of First-line Treatment for Extensive-stage Small Cell Lung Cancer Using a Combination Therapy of Trilaciclib, Envafolimab, Etoposide, and C","aka":[],"tldr":"A phase 2 trial of carboplatin and trilaciclib in lung cancer, run by Shanghai Chest Hospital, now recruiting.","summary":"Efficacy and Safety of First-line Treatment for Extensive-stage Small Cell Lung Cancer Using a Combination Therapy of Trilaciclib, Envafolimab, Etoposide, and Carboplatin is a phase 2, randomised interventional study registered as NCT06698965 by Shanghai Chest Hospital, with a registry enrolment figure of 52 participants, started 2024-10-13 and due to reach its primary completion in 2029-10-31. Interventions recorded: Chemotherapy （Etoposide and Carboplatin）; Immunotherapy （Envafolimab）; Trilaciclib. Conditions listed: Lung Cancer, Small Cell. Primary outcome: The incidence of grade ≥ 3 neutropenia during chemotherapy treatment. Lung eligibility wording from the registry: \"* Small cell lung cancer (SCLC) confirmed by histology or cytology;\". Sites: China. No results are recorded here; the registry entry is the source.","status":"recruiting","asOf":"2026-09-25","links":[{"label":"ClinicalTrials.gov NCT06698965","url":"https://clinicaltrials.gov/study/NCT06698965"}],"tags":["ctgov-ingest","lung-deep-dive"],"related":[],"cancers":["extensive-stage-sclc"],"sections":[],"technologies":["cytotoxic-chemotherapy","platinum"],"targets":[],"drugs":["carboplatin","trilaciclib"],"companies":["simcere"],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"nct":"NCT06698965","phase":"2","setting":"A Randomized, Controlled Phase II Clinical Study on the Efficacy and Safety of First-line Treatment for Extensive-stage Small Cell Lung Cancer Using a Combination Therapy of Trilaciclib, Envafolimab, Etoposide, and Carboplatin","sponsor":"Shanghai Chest Hospital","enrolled":52,"enrolledBasis":"registry","outcomes":[]},"route":"/trials/nct06698965/","neighbours":{"cancer":[{"id":"extensive-stage-sclc","kind":"cancer","name":"Extensive-stage small-cell lung cancer","route":"/cancers/extensive-stage-sclc/"}],"technology":[{"id":"cytotoxic-chemotherapy","kind":"technology","name":"Cytotoxic chemotherapy","route":"/technologies/cytotoxic-chemotherapy/"},{"id":"platinum","kind":"technology","name":"Platinum agents","route":"/technologies/platinum/"}],"drug":[{"id":"carboplatin","kind":"drug","name":"Carboplatin","route":"/drugs/carboplatin/"},{"id":"trilaciclib","kind":"drug","name":"Trilaciclib","route":"/drugs/trilaciclib/"}],"company":[{"id":"simcere","kind":"company","name":"Simcere Pharmaceutical","route":"/companies/simcere/"}],"term":[{"id":"lung-trials-open-today","kind":"term","name":"Lung cancer trials open today (registry snapshot)","route":"/terms/lung-trials-open-today/"}]}}